vs
Shoals Technologies Group, Inc.（SHLS）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
Shoals Technologies Group, Inc.的季度营收约是VERACYTE, INC.的1.1倍（$148.3M vs $140.6M），VERACYTE, INC.净利率更高（29.3% vs 5.5%，领先23.8%），Shoals Technologies Group, Inc.同比增速更快（38.6% vs 18.5%），VERACYTE, INC.自由现金流更多（$48.8M vs $-11.3M），过去两年Shoals Technologies Group, Inc.的营收复合增速更高（27.8% vs 20.5%）
Shoals科技集团是可再生能源及电动出行领域的电气系统平衡解决方案供应商，核心产品覆盖光伏、储能及充电桩用连接组件，主要服务北美、欧洲、亚太市场的公用事业、工商业及民用客户。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
SHLS vs VCYT — 直观对比
营收规模更大
SHLS
是对方的1.1倍
$140.6M
营收增速更快
SHLS
高出20.1%
18.5%
净利率更高
VCYT
高出23.8%
5.5%
自由现金流更多
VCYT
多$60.1M
$-11.3M
两年增速更快
SHLS
近两年复合增速
20.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $148.3M | $140.6M |
| 净利润 | $8.1M | $41.1M |
| 毛利率 | 31.6% | 72.5% |
| 营业利润率 | 11.7% | 26.4% |
| 净利率 | 5.5% | 29.3% |
| 营收同比 | 38.6% | 18.5% |
| 净利润同比 | 3.9% | 704.8% |
| 每股收益（稀释后） | $0.05 | $0.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SHLSVCYT
| Q4 25 | $148.3M | $140.6M | ||
| Q3 25 | $135.8M | $131.9M | ||
| Q2 25 | $110.8M | $130.2M | ||
| Q1 25 | $80.4M | $114.5M | ||
| Q4 24 | $107.0M | $118.6M | ||
| Q3 24 | $102.2M | $115.9M | ||
| Q2 24 | $99.2M | $114.4M | ||
| Q1 24 | $90.8M | $96.8M |
净利润SHLSVCYT
| Q4 25 | $8.1M | $41.1M | ||
| Q3 25 | $11.9M | $19.1M | ||
| Q2 25 | $13.9M | $-980.0K | ||
| Q1 25 | $-282.0K | $7.0M | ||
| Q4 24 | $7.8M | $5.1M | ||
| Q3 24 | $-267.0K | $15.2M | ||
| Q2 24 | $11.8M | $5.7M | ||
| Q1 24 | $4.8M | $-1.9M |
毛利率SHLSVCYT
| Q4 25 | 31.6% | 72.5% | ||
| Q3 25 | 37.0% | 69.2% | ||
| Q2 25 | 37.2% | 69.0% | ||
| Q1 25 | 35.0% | 69.5% | ||
| Q4 24 | 37.6% | 66.4% | ||
| Q3 24 | 24.8% | 68.2% | ||
| Q2 24 | 40.3% | 68.1% | ||
| Q1 24 | 40.2% | 64.5% |
营业利润率SHLSVCYT
| Q4 25 | 11.7% | 26.4% | ||
| Q3 25 | 13.7% | 17.4% | ||
| Q2 25 | 14.4% | -4.0% | ||
| Q1 25 | 5.4% | 2.5% | ||
| Q4 24 | 15.4% | 3.5% | ||
| Q3 24 | 4.4% | 10.4% | ||
| Q2 24 | 18.7% | 4.0% | ||
| Q1 24 | 12.8% | -4.8% |
净利率SHLSVCYT
| Q4 25 | 5.5% | 29.3% | ||
| Q3 25 | 8.7% | 14.5% | ||
| Q2 25 | 12.5% | -0.8% | ||
| Q1 25 | -0.4% | 6.2% | ||
| Q4 24 | 7.3% | 4.3% | ||
| Q3 24 | -0.3% | 13.1% | ||
| Q2 24 | 11.9% | 5.0% | ||
| Q1 24 | 5.3% | -1.9% |
每股收益（稀释后）SHLSVCYT
| Q4 25 | $0.05 | $0.50 | ||
| Q3 25 | $0.07 | $0.24 | ||
| Q2 25 | $0.08 | $-0.01 | ||
| Q1 25 | $0.00 | $0.09 | ||
| Q4 24 | $0.04 | $0.07 | ||
| Q3 24 | $0.00 | $0.19 | ||
| Q2 24 | $0.07 | $0.07 | ||
| Q1 24 | $0.03 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3M | $362.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $600.0M | $1.3B |
| 总资产 | $904.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资SHLSVCYT
| Q4 25 | $7.3M | $362.6M | ||
| Q3 25 | $8.6M | $315.6M | ||
| Q2 25 | $4.7M | $219.5M | ||
| Q1 25 | $35.6M | $186.1M | ||
| Q4 24 | $23.5M | $239.1M | ||
| Q3 24 | $11.1M | $274.1M | ||
| Q2 24 | $3.2M | $235.9M | ||
| Q1 24 | $15.2M | $209.2M |
总债务SHLSVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $141.8M | — | ||
| Q4 24 | $141.8M | — | ||
| Q3 24 | $141.8M | — | ||
| Q2 24 | $146.8M | — | ||
| Q1 24 | $168.8M | — |
股东权益SHLSVCYT
| Q4 25 | $600.0M | $1.3B | ||
| Q3 25 | $589.6M | $1.3B | ||
| Q2 25 | $575.4M | $1.2B | ||
| Q1 25 | $558.9M | $1.2B | ||
| Q4 24 | $556.8M | $1.2B | ||
| Q3 24 | $545.2M | $1.2B | ||
| Q2 24 | $544.6M | $1.1B | ||
| Q1 24 | $554.0M | $1.1B |
总资产SHLSVCYT
| Q4 25 | $904.1M | $1.4B | ||
| Q3 25 | $851.8M | $1.4B | ||
| Q2 25 | $795.0M | $1.3B | ||
| Q1 25 | $788.4M | $1.3B | ||
| Q4 24 | $793.1M | $1.3B | ||
| Q3 24 | $801.3M | $1.3B | ||
| Q2 24 | $788.4M | $1.2B | ||
| Q1 24 | $825.3M | $1.2B |
负债/权益比SHLSVCYT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.25× | — | ||
| Q4 24 | 0.25× | — | ||
| Q3 24 | 0.26× | — | ||
| Q2 24 | 0.27× | — | ||
| Q1 24 | 0.30× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.1M | $52.6M |
| 自由现金流经营现金流 - 资本支出 | $-11.3M | $48.8M |
| 自由现金流率自由现金流/营收 | -7.6% | 34.7% |
| 资本支出强度资本支出/营收 | 4.8% | 2.7% |
| 现金转化率经营现金流/净利润 | -0.50× | 1.28× |
| 过去12个月自由现金流最近4个季度 | $-16.0M | $126.6M |
8季度趋势，按日历期对齐
经营现金流SHLSVCYT
| Q4 25 | $-4.1M | $52.6M | ||
| Q3 25 | $19.4M | $44.8M | ||
| Q2 25 | $-13.8M | $33.6M | ||
| Q1 25 | $15.6M | $5.4M | ||
| Q4 24 | $14.0M | $24.5M | ||
| Q3 24 | $15.7M | $30.0M | ||
| Q2 24 | $37.8M | $29.6M | ||
| Q1 24 | $12.9M | $-9.0M |
自由现金流SHLSVCYT
| Q4 25 | $-11.3M | $48.8M | ||
| Q3 25 | $9.0M | $42.0M | ||
| Q2 25 | $-26.0M | $32.3M | ||
| Q1 25 | $12.3M | $3.5M | ||
| Q4 24 | $12.5M | $20.4M | ||
| Q3 24 | $13.3M | $27.7M | ||
| Q2 24 | $35.8M | $26.8M | ||
| Q1 24 | $10.4M | $-11.1M |
自由现金流率SHLSVCYT
| Q4 25 | -7.6% | 34.7% | ||
| Q3 25 | 6.6% | 31.8% | ||
| Q2 25 | -23.5% | 24.8% | ||
| Q1 25 | 15.4% | 3.1% | ||
| Q4 24 | 11.6% | 17.2% | ||
| Q3 24 | 13.0% | 23.9% | ||
| Q2 24 | 36.1% | 23.4% | ||
| Q1 24 | 11.4% | -11.5% |
资本支出强度SHLSVCYT
| Q4 25 | 4.8% | 2.7% | ||
| Q3 25 | 7.7% | 2.1% | ||
| Q2 25 | 11.0% | 1.0% | ||
| Q1 25 | 4.0% | 1.6% | ||
| Q4 24 | 1.4% | 3.5% | ||
| Q3 24 | 2.3% | 1.9% | ||
| Q2 24 | 2.0% | 2.4% | ||
| Q1 24 | 2.7% | 2.2% |
现金转化率SHLSVCYT
| Q4 25 | -0.50× | 1.28× | ||
| Q3 25 | 1.63× | 2.34× | ||
| Q2 25 | -1.00× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | 1.79× | 4.80× | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | 3.21× | 5.16× | ||
| Q1 24 | 2.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SHLS
| System Solutions | $122.0M | 82% |
| Components | $26.3M | 18% |
VCYT
| Testing | $135.8M | 97% |
| Products | $3.8M | 3% |
| Biopharmaceutical And Other | $686.0K | 0% |
